How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,224 results for

"grant funding" or "obtaining grants" or "getting grants" or "grant awards" or (grants and "how to")

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

17861. XK469R in Treating Patients With Refractory Hematologic Cancer

(NCI) Investigators Layout table for investigator information Principal Investigator: Francis Giles M.D. Anderson Cancer Center More Information Go to Layout table for additonal information Responsible Party: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Other Study ID Numbers: NCI-2012-02633 MDA-2004-0154 U10CA62461 ( Other Grant/Funding Number: US NIH Grant/Contract Award Number ) CDR0000393836 ( Registry Identifier: PDQ (Physician Data Query) ) First Posted: November 9, 2004

2004 Clinical Trials

17862. Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation

to Additional Information: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Atrial Fibrillation Network ClinicalTrials.gov Identifier: Other Study ID Numbers: AFNET-B10 Grant No 01GI0204 ( Other Grant/Funding Number: BMBF ) First Posted: December 6, 2004 Last Update Posted: September 11, 2012 Last Verified: September 2012 Keywords provided by Atrial Fibrillation Network: atrial fibrillation angiotensin

2004 Clinical Trials

17863. Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease

Principal Investigator: Lynne H. Shinto, ND Oregon Health and Science University More Information Go to Publications of Results: Other Publications: Layout table for additonal information Responsible Party: Lynne Shinto, ND, MPH, Oregon Health and Science University ClinicalTrials.gov Identifier: Other Study ID Numbers: IA0062 AG08017 ( Other Grant/Funding Number: National Institute of Aging ) First Posted: August 26, 2004 Results First Posted: February 26, 2010 Last Update Posted: July 21, 2017 Last

2004 Clinical Trials

17864. CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

: CDR0000385687 BUMC-H-23235 ( Other Identifier: Boston University Medical Center IRB ) CELGENE-RV-AMYL-PI-003 ( Other Grant/Funding Number: Celgene ) First Posted: September 9, 2004 Results First Posted: February 20, 2017 Last Update Posted: February 20, 2017 Last Verified: December 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by Vaishali Sanchorawala, Boston Medical Center: primary systemic amyloidosis Additional relevant MeSH terms: Layout table for MeSH (...) : February 20, 2017 Sponsor: Vaishali Sanchorawala Collaborator: Celgene Corporation Information provided by (Responsible Party): Vaishali Sanchorawala, Boston Medical Center Study Details Study Description Go to Brief Summary: RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis. Condition

2004 Clinical Trials

17865. SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

-Orange Campus More Information Go to Layout table for additonal information Responsible Party: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Other Study ID Numbers: NCI-2012-02623 UCI#02-55 N01CN25139 ( Other Grant/Funding Number: US NIH Grant/Contract Award Number ) CDR0000383786 ( Registry Identifier: PDQ (Physician Data Query) ) First Posted: September 8, 2004 Last Update Posted: June 3, 2013 Last Verified: March 2013 Additional relevant MeSH terms: Layout table for MeSH terms (...) : National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells. Vaccines, such as SGN-00101, may make the body build an immune response to kill human papillomavirus and abnormal cervical cells and may

2004 Clinical Trials

17866. Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

. PURPOSE: This phase I trial is studying the side effects and best dose of gene-modified white blood cells when given together with cyclophosphamide, fludarabine, vaccine therapy, and aldesleukin and to see how well it works in treating patients with metastatic melanoma. Condition or disease Intervention/treatment Phase Melanoma (Skin) Biological: MART-1:27-35 peptide vaccine Biological: aldesleukin Biological: filgrastim Biological: incomplete Freund's adjuvant Biological: therapeutic autologous (...) using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00091104 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 NCI - Surgery Branch Bethesda, Maryland, United States, 20892-1201 Sponsors and Collaborators National Institutes of Health Clinical Center (CC) National Cancer

2004 Clinical Trials

17867. Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Combining vaccine therapy with chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This clinical trial is studying how well giving vaccine therapy together with paclitaxel, carboplatin, and radiation therapy works in treating patients with stage III non-small cell lung cancer that cannot be removed with surgery. Condition or disease Intervention/treatment (...) doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00091039 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Sponsors and Collaborators National Cancer Institute (NCI) Investigators Layout table for investigator information Principal

2004 Clinical Trials

17868. Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Posted : July 10, 2018 Sponsor: Alliance for Clinical Trials in Oncology Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Alliance for Clinical Trials in Oncology Study Details Study Description Go to Brief Summary: This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies (...) . PURPOSE: This randomized phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma. Condition or disease Intervention/treatment Phase Large B Cell Lymphoma Biological: rituximab Drug: cyclophosphamide Drug: doxorubicin Drug: vincristine Drug: prednisone Drug: etoposide Drug: filgrastim Drug: pegfilgrastim Phase 3 Detailed Description: PRIMARY OBJECTIVES: I

2005 Clinical Trials

17869. SELESTIAL: Trial of Insulin to Control Blood Sugar After Acute Stroke Using Magnetic Resonance Imaging (MRI) End-Points

lactic acid. When performed in conjunction with conventional MRI scanning, the relationship of lactate accumulation to stroke expansion can be established. SELESTIAL is a randomised, placebo-controlled trial of insulin infusions of 24 or 72 hours (h) duration in acute stroke patients with hyperglycaemia, to establish whether insulin prevents lactate accumulation over the initial 72h after stroke, how this relates to stroke evolution, and the effect of treatment on stroke size and clinical outcomes (...) Hospitals NHS Trust The Stroke Association, United Kingdom Investigators Layout table for investigator information Principal Investigator: Keith Muir, MD University of Glasgow More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 04/S0702/58 Grant No: TSA 06/03 MREC Ref: 04/MRE00/31 R&D Ref: R030295 First Posted: July 28, 2005 Last Update Posted: February 1, 2006 Last Verified: July 2005 Keywords provided by University of Glasgow: stroke

2005 Clinical Trials

17870. Triptorelin for Ovary Protection in Childhood Onset Lupus

Hospital Medical Center, Cincinnati ClinicalTrials.gov Identifier: Obsolete Identifiers: NCT00088244 Other Study ID Numbers: 2008-1045 FD-R-00239 ( Other Grant/Funding Number: FDA OOPD ) First Posted: July 28, 2005 Last Update Posted: July 28, 2014 Last Verified: July 2014 Keywords provided by Dr. Hermine Brunner, Children's Hospital Medical Center, Cincinnati: SLE Lupus Ovarian damage Menopause Additional relevant MeSH terms: Layout table for MeSH terms Lupus Erythematosus, Systemic Connective Tissue

2005 Clinical Trials

17871. Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training

for additonal information Responsible Party: New York University School of Medicine ClinicalTrials.gov Identifier: Other Study ID Numbers: H12444-01 A NAM MD 18 ( Other Grant/Funding Number: Forest Laboratories ) First Posted: July 19, 2005 Results First Posted: July 14, 2016 Last Update Posted: October 25, 2016 Last Verified: September 2016 Keywords provided by New York University School of Medicine: Alzheimer's disease caregiver training caregiver counseling individualized management memantine dementia (...) ] The RMBPC is a 24 item rating scale of the frequency of memory and behavioral problems in the AD subject and of how upset or "bothered" their caregivers react. Frequency is rated from 0 (least frequent) to 4 (most frequent) and caregiver reaction is rated from 0 (not at all) to 4 (extremely bothered or upset). Higher scores indicate more frequent memory and behavioral problems in the subject with AD as well as a more upset or bothered caregiver. Possible scores range from 0 to 96. Change From Baseline

2005 Clinical Trials

17872. Comparison of Air and Expansile Gas in Pneumatic Retinopexy

to Publications of Results: Layout table for additonal information Responsible Party: Yosanan Yospaiboon, Professor, Khon Kaen University ClinicalTrials.gov Identifier: Other Study ID Numbers: HE470116 TRF470116 ( Other Grant/Funding Number: Thailand Research Fund ) First Posted: July 18, 2005 Last Update Posted: March 9, 2012 Last Verified: March 2012 Keywords provided by Yosanan Yospaiboon, Khon Kaen University: retinal detachment pneumatic retinopexy Additional relevant MeSH terms: Layout table for MeSH

2005 Clinical Trials

17873. Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Sponsors and Collaborators National Cancer Institute (NCI) Investigators Layout table for investigator information Principal Investigator: Naomi Balzer-Haas Princess Margaret Hospital Phase 2 Consortium More Information Go to Publications of Results: Layout table for additonal information Responsible Party: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Other Study ID Numbers: NCI-2009-00099 PHL-040 ( Other Grant/Funding (...) Number: N01CM62203 ) CDR0000436851 ( Other Grant/Funding Number: N01CM62203 ) First Posted: July 21, 2005 Results First Posted: October 3, 2014 Last Update Posted: January 29, 2019 Last Verified: January 2019 Additional relevant MeSH terms: Layout table for MeSH terms Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Vorinostat Antineoplastic Agents Histone Deacetylase Inhibitors

2005 Clinical Trials

17874. Stereotactic Radiotherapy (SRT) Liver (COLD 1)

Frame: assessment: pre-treatement, 1, 3, 6,12 months post ] To evaluate changes in liver function following SRT. [ Time Frame: 3 to 12 months ] To evaluate patterns of breathing at and during RT. [ Time Frame: during radiation treatment only ] To develop more confidence in a revised normal tissue complication probability (NTCP) model for radiation induced liver toxicity and collect preliminary data to determine how the liver responds to radiation. [ Time Frame: at 3 months post RT ] To determine (...) for additonal information Responsible Party: University Health Network, Toronto ClinicalTrials.gov Identifier: Other Study ID Numbers: UHN REB 03-0295-C ASCO Clinical Research Grant First Posted: September 9, 2005 Last Update Posted: September 25, 2018 Last Verified: September 2018 Additional relevant MeSH terms: Layout table for MeSH terms Neoplasms Neoplasm Metastasis Liver Neoplasms Neoplastic Processes Pathologic Processes Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver

2005 Clinical Trials

17875. Intravenous (IV) Pantoprazole in Erosive Esophagitis

University More Information Go to Layout table for additonal information Responsible Party: Dr. Qiang Cai MD/PhD, Professor, Emory University ClinicalTrials.gov Identifier: Other Study ID Numbers: 259-2004 3001K-200042 ( Other Grant/Funding Number: Wyeth ) First Posted: August 24, 2005 Last Update Posted: July 31, 2013 Last Verified: July 2013 Keywords provided by Dr. Qiang Cai MD/PhD, Emory University: IV pantoprazole Esophagitis Additional relevant MeSH terms: Layout table for MeSH terms Esophagitis

2005 Clinical Trials

17876. Improving Pediatric Safety and Quality With Health Care Information Technology

Number): Layout table for additonal information Responsible Party: Timothy G Ferris, Mass General Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: 2004-P-002027 HS015002-01 ( Other Grant/Funding Number: AHRQ ) First Posted: August 25, 2005 Last Update Posted: July 21, 2011 Last Verified: July 2011 Keywords provided by Massachusetts General Hospital: Parent Experience of Care Quality Improvement Medication Errors Abnormal Lab Values Guideline Adherence

2005 Clinical Trials

17877. Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

for investigator information Principal Investigator: Jonathan Strosberg, MD H. Lee Moffitt Cancer Center & Research Institute / University of South Florida More Information Go to Additional Information: Layout table for additonal information Responsible Party: H. Lee Moffitt Cancer Center and Research Institute ClinicalTrials.gov Identifier: Other Study ID Numbers: MCC-13449 R21 CA10135 ( Other Grant/Funding Number: NCI ) XEL390 ( Other Identifier: Roche ) 2005-0729 ( Other Identifier: Pfizer ) First Posted

2005 Clinical Trials

17878. Trial of Realignment Therapy for Treatment of Medial Knee Osteoarthritis

and Collaborators Boston University Investigators Layout table for investigator information Principal Investigator: David J Hunter Boston University More Information Go to Layout table for additonal information Responsible Party: Boston University ClinicalTrials.gov Identifier: Other Study ID Numbers: H-24147 H133G040201 ( Other Grant/Funding Number: NIDRR ) First Posted: July 28, 2005 Results First Posted: June 29, 2017 Last Update Posted: June 29, 2017 Last Verified: May 2017 Individual Participant Data (IPD

2005 Clinical Trials

17879. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

to Additional Information: Publications of Results: Other Publications: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: New England Research Institutes ClinicalTrials.gov Identifier: Other Study ID Numbers: 160 HHSN268200425207C ( Other Grant/Funding Number: NIH contract ) First Posted: October 15, 2004 Results First Posted: March 2, 2015 Last Update Posted: March 2, 2015 Last Verified: January 2014

2004 Clinical Trials

17880. Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

(NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die. Condition or disease Intervention/treatment Phase Metastatic Gastrointestinal Carcinoid Tumor Pulmonary (...) have tumor lesions accessible for biopsy for correlative studies; in cases where there is a medical contraindication to tumor biopsy, exception may be granted upon discussion with the Principal Investigator/Chair The effects of CCI-779 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry

2004 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>